SPOTLIGHT: Genta restructures

With the FDA unwilling to budge on its decision to demand more data before it approves the leukemia drug Genasense, Genta announced plans to cut 16 employees--about 30 percent of its workforce--as it restructures to conserve cash. Release

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.